However, as investors, we care about the stock price years down the line and what Eli Lilly will do in the next 3 to 5 years and beyond. That is why 24/7 Wall Street looks at projected revenue ...
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...
In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Geoff Meacham ...
Most U.S. stocks rose following an encouraging update on inflation, but drops for Eli Lilly and some other influential stocks ...
Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback